Quantum BioPharma Receives Health Canada Product License for Qlarity Natural Health Product
Quantum BioPharma Ltd. has secured Health Canada approval for its Qlarity natural health product, expanding its market reach and revenue potential through regulatory clearance for cognitive and energy support supplements.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has obtained a Product License from Health Canada for its natural health product Qlarity, marking a significant regulatory milestone for the biopharmaceutical company. The license, identified as PN 80144141, authorizes the sale of Qlarity in Canada with recommended uses including support for energy production, metabolism, electrolyte balance, mental alertness, cognitive performance, endurance, and fatigue reduction. This development follows Quantum's previous licensing of a similar product in the United States under the brand name unbuzzd(TM), demonstrating the company's strategic expansion into regulated health markets.
The approval from Health Canada carries substantial implications for Quantum BioPharma's business model and revenue streams. According to the company's corporate structure, Quantum retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, and receives royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. This licensing framework, combined with the new Canadian market entry, positions Quantum to benefit from multiple revenue channels while maintaining 100% rights to develop similar products for pharmaceutical and medical applications. The company's portfolio approach extends beyond consumer health products to include strategic investments through its subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Quantum BioPharma's broader research focus remains on developing treatments for neurodegenerative and metabolic disorders and alcohol misuse through its wholly owned subsidiary Lucid Psycheceuticals Inc. The company's lead compound, Lucid-MS, represents a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models, addressing the underlying mechanism of multiple sclerosis. The Health Canada approval for Qlarity provides immediate market access while supporting the company's long-term pharmaceutical development goals. Additional information about Quantum BioPharma is available in the company's newsroom at https://ibn.fm/QNTM.